LAB Advances Treeline Merger With $30M Cash Inflow and Strategic Divestiture

• Standard BioTools received approximately $30 million from Illumina to buy out contingent SomaLogic payments, boosting pro forma cash for the Treeline merger.
• The company agreed to sell its Mass Cytometry business to Multiplex Bio, allowing it to exit non-core operations and focus on the pending all-stock combination.
• The U.S. Federal Trade Commission early-terminated the waiting period for the Treeline merger, removing a significant regulatory hurdle ahead of the expected close.
• Analysts remain cautious due to deteriorating financial metrics, including revenue declines and operating losses, despite the strategic portfolio streamlining.

Standard BioTools Inc. (LAB) has moved decisively to streamline its corporate structure and finalize its pending merger with Treeline Biosciences. The company announced a series of strategic transactions designed to optimize its balance sheet and eliminate non-core assets. These moves include a significant cash infusion from Illumina and the divestiture of its Mass Cytometry business.

The company received approximately $30 million in cash from Illumina, Inc. This payment represents a buyout of the 2026 earnout and all future royalty payments related to Illumina’s acquisition of Standard BioTools’ SomaLogic business. This cash infusion increases the company’s pro forma net cash, which supports the valuation mechanics of the pending all-stock merger with Treeline. The transaction simplifies the financial contours of the merger and provides immediate liquidity.

In a separate development, Standard BioTools agreed to sell its Mass Cytometry business to Multiplex Bio. This new entity is led by industry veterans Michael Johnson, Tom Villani, and Charles Coffman. Multiplex Bio will continue commercializing the CyTOF and Hyperion product lines under the Standard BioTools brand. The deal is valued at up to $10 million via a seller’s note and potential milestones. This divestiture allows Standard BioTools to exit non-core operations and focus entirely on the Treeline combination.

What is the timeline for the Treeline merger?

The U.S. Federal Trade Commission early-terminated the waiting period for the Treeline merger under the Hart-Scott-Rodino Act. This regulatory clearance removes a major uncertainty for the transaction. Standard BioTools expects the Treeline transaction to close by the end of 2026, subject to stockholder approval. The sale of the Mass Cytometry business is expected to close substantially concurrently with the Treeline transaction.

CEO Michael Egholm stated that the sale of the Mass Cytometry business allows the company to steward its products through specialized leadership while it completes the Treeline merger. The combination with Treeline is intended to create a more focused entity in the single-cell multiomics space. The integration of these two companies aims to capture growth in precision medicine and oncology research.

The global single-cell multiomics market is projected to grow significantly, driven by the adoption of single-cell genomics and AI-driven bioinformatics. Standard BioTools operates in a competitive landscape alongside major players like 10x Genomics and Danaher. The strategic shift is designed to position the combined entity to compete more effectively in this expanding market.

How do financial metrics impact investor sentiment?

Despite the strategic progress, analysts remain cautious regarding Standard BioTools' near-term financial performance. The company is expected to report a loss of 1 cent per share for the upcoming earnings period. Consensus estimates project revenue of approximately $20.8 million for the second quarter of 2026. These figures reflect ongoing profitability challenges in the life sciences tools sector.

Historical data shows significant volatility in the company's financial results. In the second quarter of 2025, reported revenue missed estimates by over 45 percent. However, the company recently beat estimates in the fourth quarter of 2025 and the first quarter of 2026. The anticipated loss for the upcoming quarter underscores the high capital intensity and competitive dynamics inherent in the bioprocessing and automation markets.

Analyst ratings currently reflect a neutral outlook. LAB holds a Hold rating with a price target of $1.35. Spark, TipRanks’ AI Analyst, rates LAB as Neutral, citing deteriorating financial performance. The rating highlights sharp year-over-year revenue declines, large operating losses, and ongoing negative free cash flow. Technical momentum indicators also remain negative, with the stock trading near the lower end of its 52-week range.

Institutional investors have shown mixed activity in recent quarters. Russell Investments Group Ltd. significantly boosted its position in the third quarter, increasing holdings by nearly 3,000 percent. Other institutional moves include new positions or purchases by CIBC World Markets Corp and Aigen Investment Management LP. These adjustments suggest varying levels of confidence in the company's strategic direction.

The broader market context includes intensifying pressure from larger competitors. Danaher has strengthened its life sciences capabilities through investments in Cytiva and Beckman Coulter. This expansion intensifies competition for standalone entities like Standard BioTools. Investors are closely watching how the company manages its cost structure and leverages its technology platforms to achieve sustainable growth.

The strategic divestitures and financing adjustments are viewed as necessary steps to finalize the merger. By shedding non-core assets and securing cash from Illumina, Standard BioTools is consolidating its focus. The success of the Treeline merger will likely depend on the combined entity's ability to navigate the competitive single-cell genomics landscape. Investors will be monitoring future earnings reports for signs of margin improvement and revenue stabilization.